
Valiant Organics Q1 FY27: consol PAT triples to ₹29.3 Cr as Pharma turns profitable
specialty chemicals · pharma segment · margin expansion
BSE: 540145
P/L Snapshot
Q2 FY27 · standalone
Shareholding
Pattern breakdown
P/L Trends
(in crores)
Corporate Events
Board Meeting
The Board of Directors meeting is scheduled to consider and …
BSE Filing ↗Board Meeting
The Company has initiated sending letters containing the web…
BSE Filing ↗Board Meeting
The meeting of the Board of Directors of the Company is sche…
BSE Filing ↗Board Meeting
The Nomination and Remuneration Committee (NRC) of the Board…
BSE Filing ↗Board Meeting
Approval Of Financial Results For The Quarter And Half Year …
BSE Filing ↗Board Meeting
Audited Standalone & Consolidated Financial results of the C…
BSE Filing ↗Board Meeting
[Consider and approve The Audited Standalone & Consolidated …
BSE Filing ↗Board Meeting
Consider and approve The Audited Standalone & Consolidated F…
BSE Filing ↗Board Meeting
Consider and approve The Audited Standalone & Consolidated F…
BSE Filing ↗